BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

118 related articles for article (PubMed ID: 1878668)

  • 1. What is graft versus host disease?
    van Bekkum DW
    Bone Marrow Transplant; 1991; 7 Suppl 2():110-1. PubMed ID: 1878668
    [No Abstract]   [Full Text] [Related]  

  • 2. Immunosuppression, graft-versus-host disease, and infection after bone marrow transplantation.
    Kramer BS; Elfenbein GJ
    J Fla Med Assoc; 1984 May; 71(5):321-8. PubMed ID: 6429272
    [No Abstract]   [Full Text] [Related]  

  • 3. Graft versus host disease prophylaxis today.
    Martelli MF; Aversa F
    Bone Marrow Transplant; 1991; 7 Suppl 2():112-6. PubMed ID: 1908726
    [No Abstract]   [Full Text] [Related]  

  • 4. Graft-versus-host disease.
    Gatti RA; Kersey JH; Yunis EJ; Good RA
    Prog Clin Pathol; 1973; 5():1-18. PubMed ID: 4150104
    [No Abstract]   [Full Text] [Related]  

  • 5. [Gastroenterological complications after bone marrow transplantation].
    Ratajczak MZ; Duziak M
    Pol Tyg Lek; 1990 Aug 20-27; 45(34-35):716-20. PubMed ID: 2075143
    [No Abstract]   [Full Text] [Related]  

  • 6. Allospecific CD8+ Tc1 and Tc2 populations in graft-versus-leukemia effect and graft-versus-host disease.
    Fowler DH; Breglio J; Nagel G; Eckhaus MA; Gress RE
    J Immunol; 1996 Dec; 157(11):4811-21. PubMed ID: 8943383
    [TBL] [Abstract][Full Text] [Related]  

  • 7. CD4+CD25+ regulatory T cells preserve graft-versus-tumor activity while inhibiting graft-versus-host disease after bone marrow transplantation.
    Edinger M; Hoffmann P; Ermann J; Drago K; Fathman CG; Strober S; Negrin RS
    Nat Med; 2003 Sep; 9(9):1144-50. PubMed ID: 12925844
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Posttransfusion graft vs host disease].
    Muñoz MC; Hernández M; Rifón J; Panizo C; Rodríguez M
    Sangre (Barc); 1998 Feb; 43(1):55-8. PubMed ID: 9580428
    [No Abstract]   [Full Text] [Related]  

  • 9. The reconstitution of cellular immunity after bone marrow transplantation in children.
    Lanfranchi A; Porta F; Locatelli F; Zecca M; Nespoli L; Albertini A
    Haematologica; 1992; 77(4):336-47. PubMed ID: 1427444
    [No Abstract]   [Full Text] [Related]  

  • 10. Rapid lethality of hosts by interleukin-12 following H-2 compatible allogeneic bone marrow transplantation: Reminiscence of gut-associated acute graft-versus-host reaction.
    Schmitt M; Taniguchi M; Yoshida T; Miyahara Y; Gu X; Mukai K; Yagita H; Dohner H; Shiku H
    Int J Oncol; 2002 Oct; 21(4):795-801. PubMed ID: 12239618
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Proliferation-based T-cell selection for immunotherapy and graft-versus-host-disease prophylaxis in the context of bone marrow transplantation.
    Pachnio A; Dietrich S; Klapper W; Humpe A; Schwake M; Sedlacek R; Gramatzki M; Beck C
    Bone Marrow Transplant; 2006 Jul; 38(2):157-67. PubMed ID: 16820783
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Donor antigen-presenting cells regulate T-cell expansion and antitumor activity after allogeneic bone marrow transplantation.
    Li JM; Waller EK
    Biol Blood Marrow Transplant; 2004 Aug; 10(8):540-51. PubMed ID: 15282532
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Bone marrow augmentation of kidney allografts can cause graft-versus-host disease in immunosuppressed recipients.
    Pirenne J; Moon C; Gruessner A; Benedetti E; Nakhleh RE; Uckun F; Gruessner RW
    Transplant Proc; 1996 Apr; 28(2):941-2. PubMed ID: 8623472
    [No Abstract]   [Full Text] [Related]  

  • 14. A two-phase pathogenesis of graft-versus-host disease in mice.
    van Leeuwen L; Guiffre A; Atkinson K; Rainer SP; Sewell WA
    Bone Marrow Transplant; 2002 Jan; 29(2):151-8. PubMed ID: 11850710
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Orthotopic liver transplantation for acute grade IV hepatic graft-versus-host disease following bone marrow transplantation.
    Figuera A; Tomás JF; Otero MJ; Moreno E; García I; Fernández-Rañada JM
    Am J Hematol; 1996 May; 52(1):68-9. PubMed ID: 8638625
    [No Abstract]   [Full Text] [Related]  

  • 16. [The skin manifestations of the graft vs. host reaction].
    Biriukov AV; Baranov AE; Selidovkin GD; Evseeva LV; Getling ZM; Persina IS
    Vestn Dermatol Venerol; 1990; (5):16-9. PubMed ID: 2402935
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Late effects after allogeneic bone marrow transplantation.
    Dicke KA
    Bone Marrow Transplant; 1994; 14 Suppl 4():S11-3. PubMed ID: 7728118
    [No Abstract]   [Full Text] [Related]  

  • 18. Pediatric bone marrow transplantation.
    Chan KW
    Pediatr Dent; 1995; 17(4):291-3. PubMed ID: 7567633
    [No Abstract]   [Full Text] [Related]  

  • 19. [Recovery of immune function after bone marrow transplantation].
    Takagi S; Miura Y
    Rinsho Ketsueki; 1987 Mar; 28(3):323-30. PubMed ID: 3302350
    [No Abstract]   [Full Text] [Related]  

  • 20. Suppression of graft-versus-host disease and amplification of graft-versus-tumor effects by activated natural killer cells after allogeneic bone marrow transplantation.
    Asai O; Longo DL; Tian ZG; Hornung RL; Taub DD; Ruscetti FW; Murphy WJ
    J Clin Invest; 1998 May; 101(9):1835-42. PubMed ID: 9576746
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.